Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Development of a recombinant immunotoxin for the immunotherapy of autoreactive lymphocytes expressing MOG-specific BCRs.
Combination therapy of interferon Beta-1b and tacrolimus: a pilot safety study.
Switch to natalizumab vs fingolimod in active relapsing-remitting multiple sclerosis.
American Neurological Association Annual Meeting
Neurons and astroglia govern microglial endotoxin tolerance through macrophage colony-stimulating factor receptor-mediated ERK1/2 signals.
Astrocyte-derived lactosylceramide implicated in multiple sclerosis.
SigmaPharm Laboratories Products
Enhancement of Chemotactic Cell Aggregation by Haptotactic Cell-To-Cell Interaction.
The Role of Endogenous IFN-β in the Regulation of Th17 Responses in Patients with Relapsing-Remitting Multiple Sclerosis.
Paucity and Inconsistency: A Systematic Review and Critique of Budget Impact Analyses of Disease-Modifying Therapies for Multiple Sclerosis in the UK and the Implications for Policy in the UK.
IL-17 and GM-CSF Expression Are Antagonistically Regulated by Human T Helper Cells.
Erratum to: Antibody-mediated neutralization of myelin-associated EphrinB3 accelerates CNS remyelination.
Gordon Research Conference on Synaptic Dysfunction and Neurodegeneration
10% liquid human immunoglobulin (KIOVIG(®)) for immunomodulation in autoimmune disorders.
Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulforaphane by promoting M2 polarization of microglia.
[Assessment of the pain patients with the multiple sclerosis after applying the physiotherapy treatment].
Biogen Idec receives notification of PDUFA date extension for PLEGRIDY™ (peginterferon beta-1a)
Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study.
Sphingosine-1-Phosphate (S1P) Impacts Presynaptic Functions by Regulating Synapsin I Localization in the Presynaptic Compartment.
'Clinically definite benign multiple sclerosis', an unwarranted conceptual hodgepodge: evidence from a 30-year observational study.
Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease.
Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease.
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
Dimethyl fumarate (BG-12, Tecfidera) approved for use by the NHS in Scotland

Pages